Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) is pleased to announce that additional results of its recently completed international Phase III trial of Bronchitol in patients with cystic fibrosis have been presented at the 2009 European Cystic Fibrosis Conference in Brest, France.

The results were presented to the conference on Friday 12 June by Dr Diana Bilton of the Royal Brompton Hospital, London.

The trial was a multi-centre, randomised, double blind, placebo controlled, 26 week study, with an optional further 6 month open label uncontrolled period. It was conducted in 40 centres in the United Kingdom, Ireland, Australia and New Zealand.

The primary endpoint of the trial was to assess whether Bronchitol improves lung function as measured by a change in FEV1 when administered twice per day for six months.

The key secondary endpoint of the trial was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, rhDNase. Additional endpoints included changes in the Forced Vital Capacity of the lung, pulmonary exacerbations and antibiotic use.

Safety evaluation included the incidence of adverse events and the microbiology of sputum samples.

    Clinical Results
    -- There was a clinically meaningful change from baseline (119mL) and
       placebo (93mL) at week 26 with Bronchitol for FEV1 (p<0.001).
       Importantly, treatment with Bronchitol showed an immediate and
       sustained improvement in lung function (FEV1) over the 26 weeks
       (p<0.001).
    -- For the subgroup of patients on concomitant rhDNase there was also a
       significant improvement in FEV1 from baseline (88mL) and from placebo
       (109mL) at we
'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 18, 2014 Reports from ... the United States suffer from one or more chronic ... or cancer. Medication can address some of these diseases, ... activities that many sufferers face. While implanted nerve stimulation ... stimulate the whole nerve, which can induce side effects. ...
(Date:12/19/2014)... CA (PRWEB) December 18, 2014 With ... limited time special on Sartorius Biohit products . ... on mLINE pipettes, Picus Electronic Pipette Trade-in Program, and ... Health and Safety officers around the world. They are ... pipetting. Other features include:, ,     Full volume ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... Achim Noack has been named global vice ... this position, Noack will assist Jerry Stoller, CEO and ... strategy and supervise global marketing management and implementation of ... knowledge and experience in the crop protection industry,” says ... innovative thinking will be a great asset for Stoller ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... and Other Packaging Uses, MELBOURNE, Australia, and ... ) and Plantic Technologies Limited, an Australian company,specializing ... the development and sale of renewably sourced polymers ... development of new, renewably sourced,resins and sheet materials ...
... Md., Sept. 26 Micromet, Inc.,(Nasdaq: MITI ... of,novel, proprietary antibody-based products for cancer, inflammation and,autoimmune ... and,Chief Executive Officer of Micromet, will present at ... Forum in Zurich, Switzerland on,Tuesday, October 2, 2007 ...
... To Accelerate Trials and Commercialization, PALO ALTO, ... Board: AVGO), a late-stage biotechnology company that,develops central ... it had conducted an initial closing of its,private ... Company received gross proceeds of $3,110,000 and in ...
Cached Biology Technology:DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 2DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 3Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum 2Avicena Group Announces Closing of Private Offering 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... engineering at the UCLA Henry Samueli School of Engineering ... biochemistry in the UCLA Division of Physical Sciences, has ... Award from the U.S. Environmental Protection Agency. ... by leading researchers and industrial innovators who are making ...
... Insulin Suppresses Mosquito Immune System: Increasing Cases of Type II ... the mosquito immune system, according to a paper in the ... malaria might seem to go together like baseball and hotdogs, ... spread among H. sapiens . "A fair ...
... June 19, 2012 A study published in the June ... of Child and Adolescent Psychiatry found that young children ... have a higher prevalence of mental health problems and that ... from the National Survey of Child and Adolescent Well-Being II ...
Cached Biology News:UCLA's Yi Tang receives Presidential Green Chemistry Challenge Award from EPA 2UCLA's Yi Tang receives Presidential Green Chemistry Challenge Award from EPA 3Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4Tips from the Journals of the American Society for Microbiology 5Tips from the Journals of the American Society for Microbiology 6Tips from the Journals of the American Society for Microbiology 7Child welfare investigation predicts mental health problems in young children 2
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
... array system, 100-240 V, uses multiplex suspension ... analysis of up to 100 proteins and ... suspension array is composed of up to ... may be conjugated with a unique reactant ...
Biology Products: